 |
 Video: What is a Stock Split?
|
|
|
| Matinas Biopharma Holdings is a biopharmaceutical company focused on development of its product candidate: MAT9001, a purified, prescription-only omega-3 free fatty acid formulation designed for the treatment of cardiovascular and metabolic conditions; and the application of its lipid nano-crystal (LNC) platform delivery technology to solve challenges relating to the delivery of small molecules, vaccines, proteins and peptides. Co.'s lead drug candidate based on the LNC platform delivery technology is MAT2203, which is an antifungal drug. Co.'s second clinical stage LNC-based product candidate is MAT2501, an orally administered formulation of aminoglycoside antibiotic amikacin. According to our Matinas BioPharma Holdings stock split history records, Matinas BioPharma Holdings has had 0 splits. | |
|
Matinas BioPharma Holdings (MTNB) has 0 splits in our Matinas BioPharma Holdings stock split history database.
Looking at the Matinas BioPharma Holdings stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Matinas BioPharma Holdings shares, starting with a $10,000 purchase of MTNB, presented on a split-history-adjusted basis factoring in the complete Matinas BioPharma Holdings stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
07/22/2014 |
|
| End date: |
05/03/2024 |
|
| Start price/share: |
$1.17 |
|
| End price/share: |
$0.17 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-85.04% |
|
| Average Annual Total Return: |
-17.64% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,496.04 |
|
| Years: |
9.79 |
|
|
|
|
|
